Beck Lisa A, Cork Michael J, Amagai Masayuki, De Benedetto Anna, Kabashima Kenji, Hamilton Jennifer D, Rossi Ana B
Department of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
Sheffield Dermatology Research, Department of Infection, Immunity and Cardiovascular Disease (IICD), The University of Sheffield, The Medical School, Sheffield, United Kingdom.
JID Innov. 2022 Apr 26;2(5):100131. doi: 10.1016/j.xjidi.2022.100131. eCollection 2022 Sep.
Skin barrier dysfunction, a defining feature of atopic dermatitis (AD), arises from multiple interacting systems. In AD, skin inflammation is caused by host-environment interactions involving keratinocytes as well as tissue-resident immune cells such as type 2 innate lymphoid cells, basophils, mast cells, and T helper type 2 cells, which produce type 2 cytokines, including IL-4, IL-5, IL-13, and IL-31. Type 2 inflammation broadly impacts the expression of genes relevant for barrier function, such as intracellular structural proteins, extracellular lipids, and junctional proteins, and enhances skin colonization. Systemic anti‒type 2 inflammation therapies may improve dysfunctional skin barrier in AD.
皮肤屏障功能障碍是特应性皮炎(AD)的一个决定性特征,它源于多个相互作用的系统。在AD中,皮肤炎症是由宿主与环境的相互作用引起的,涉及角质形成细胞以及组织驻留免疫细胞,如2型固有淋巴细胞、嗜碱性粒细胞、肥大细胞和2型辅助性T细胞,这些细胞会产生2型细胞因子,包括白细胞介素-4(IL-4)、白细胞介素-5(IL-5)、白细胞介素-13(IL-13)和白细胞介素-31(IL-31)。2型炎症广泛影响与屏障功能相关的基因表达,如细胞内结构蛋白、细胞外脂质和连接蛋白,并促进皮肤定植。全身性抗2型炎症疗法可能会改善AD中功能失调的皮肤屏障。